- Home
- RPTX
as 04-11-2025 4:00pm EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
| Founded: | 2016 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 53.2M | IPO Year: | 2020 |
| Target Price: | $4.50 | AVG Volume (30 days): | 251.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.89 - $4.29 | Next Earning Date: | 05-06-2025 |
| Revenue: | $53,477,000 | Revenue Growth: | 4.58% |
| Revenue Growth (this year): | -89.24% | Revenue Growth (next year): | 2.61% |
Stock Insider Trading Activity of Repare Therapeutics Inc. (RPTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Forte Steve | RPTX | EVP, CHIEF FINANCIAL OFFICER | Mar 12 '25 | Sell | $1.14 | 6,884 | $7,847.76 | 54,786 | |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 12 '25 | Sell | $1.14 | 3,596 | $4,099.44 | 227,813 | |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 12 '25 | Sell | $1.14 | 21,179 | $24,144.06 | 124,394 | |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 12 '25 | Sell | $1.14 | 5,611 | $6,396.54 | 80,297 |
Latest Repare Therapeutics Inc. News
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
MT Newswires
13 days ago
Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal
Business Wire
13 days ago
Repare Therapeutics Announces Leadership Transitions
Zacks
a month ago
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Business Wire
a month ago
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Simply Wall St.
a month ago
Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Business Wire
a month ago
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
MT Newswires
2 months ago
Repare Therapeutics Chief Medical Officer to Leave
Compare RPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.